

## ASX Announcement

### Recce Pharmaceuticals Presented at the FNN/Shaw and Partners Investor Conference

**SYDNEY, Australia, 21 June 2018:** Recce Pharmaceuticals Ltd (ASX: RCE) Executive Director James Graham recently presented at Finance News Network (FNN) investor conference and talked about the growing global interest in the Company's new class of antibiotics.

To view the [full investor presentation](#), please [follow the link here](#):



To view the [FNN interview](#), please [follow the link here](#):

#### About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a [new class of synthetic antibiotics with broad spectrum activity](#) designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE<sup>®</sup> 327 has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results. Recce has a manufacturing facility in Australia and is developing clinical research partners in the USA. The Company has developed an automated process to manufacture its lead compound ahead of first-in-man clinical trials.